Details

Autor(en) / Beteiligte

• Kudenchuk, Peter J
• Brown, Siobhan P
• Daya, Mohamud
• Rea, Thomas
• Nichol, Graham
• Morrison, Laurie J
• Leroux, Brian
• Vaillancourt, Christian
• Wittwer, Lynn
• Callaway, Clifton W
• Christenson, James
• Egan, Debra
• Ornato, Joseph P
• Weisfeldt, Myron L
• Stiell, Ian G
• Idris, Ahamed H
• Aufderheide, Tom P
• Dunford, James V
• Colella, M. Riccardo
• Vilke, Gary M
• Brienza, Ashley M
• Desvigne-Nickens, Patrice
• Gray, Pamela C
• Gray, Randal
• Seals, Norman
• Straight, Ron
• Dorian, Paul

Titel

Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest

Ist Teil von

• The New England journal of medicine, 2016-05, Vol.374 (18), p.1711-1722

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In this trial, patients with out-of-hospital cardiac arrest received amiodarone, lidocaine, or placebo for shock-refractory ventricular fibrillation or pulseless ventricular tachycardia. There were no significant between-group differences in survival to hospital discharge. Out-of-hospital cardiac arrest is responsible for more than 300,000 deaths each year in North America. 1 Many out-of-hospital cardiac arrests are attributable to ventricular fibrillation or pulseless ventricular tachycardia. Although ventricular fibrillation or pulseless ventricular tachycardia is regarded as the most treatable presentation of out-of-hospital cardiac arrest because of its responsiveness to shock, 2 most defibrillation attempts do not result in sustained return of spontaneous circulation. 3 Ventricular fibrillation or pulseless ventricular tachycardia commonly persists or recurs after shock, and there is a significant inverse relationship between the duration of ventricular fibrillation or pulseless ventricular tachycardia, or the frequency of acute recurrences, and . . .